Frametact

Suzhou-based Cure Genetics has entered into a collaboration and licensing agreement with Hong Kong’s Frametact Ltd, focusing on the development of novel adeno-associated virus (AAV) vectors for therapeutics addressing familial neurological diseases. Under the terms of the deal, Frametact will pay Cure Genetics a combined USD 60 million in upfront…